Anti diabetic medications thiazolidinediones or GLP-1 receptor agonists may benefit PCa treatment

[Graham49]

Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Author links open overlay panelHaiyingCuiaYaoWangbShuoYangcGuangyuHeaZongmiaoJiangaXiaokunGanga1GuixiaWanga2

Show more Share Cite

doi.org/10.1016/j.phrs.2022... rights and content

Highlights

•For the first time, present study simultaneously assessed the effects of all conventional antidiabetic medications on risk modification of prostate cancer.

•Based on meta-analysis, the use of thiazolidinediones or glucagon-like peptide-1 receptor agonists may be associated with a lower risk of prostate cancer in patients with diabetes.

•Effect of each antidiabetic medications should be interpreted with great caution as comparison is often against use of other antidiabetic medications, which may have inherent cancer-modifying effects.

Abstract

Background

Antidiabetic medications (ADMs) may modify prostate cancer (PCa) risk in patients with diabetes mellitus (DM). Accordingly, the current study assessed the possible associations between ADMs and the risk of PCa in diabetics.

Methods

A systematic literature search (PubMed, Embase and Cochrane Library) identified studies evaluating the associations between ADMs and incidence of PCa. A meta-analysis followed PRISMA was performed using odds ratio (OR) with 95% confidence interval (CI) as effect measures.

Results

In total of 47 studies involving 3,094,152 patients with diabetes were included. Results of meta-analysis of the observational studies suggested no significant association between metformin, thiazolidinediones, sulfonylureas, insulin or dipeptidyl peptidase-4 inhibitors administration and the risk of PCa (All p-values > 0.05). Separate analysis of randomized controlled trials (RCTs) revealed a significant reduction in PCa risk with thiazolidinediones (OR = 0.55, p = 0.04) or glucagon-like peptide-1 receptor agonists (GLP-1RA) administration (OR = 0.53, p = 0.006), whereas no significant association was found in SGLT2 inhibitors (p = 0.3).

Conclusion

Thiazolidinediones or GLP-1RA administration may have benefits in PCa based on RCTs, however, further research is needed to confirm these findings.

[cesces]

Thanks Graham. Nice catch!

Healthcareunlocked is becoming a compilation of a lot of interesting research.

Of course not close to the quality of TA's blog.... but gathering in one disorganized collection, an eclectic compilation of interesting and unexpected serendipitous research.

If only we had an actively practicing Doc like Dr. Myers who was willing and able to synthesize all this information into individualized off-label "low risk / high reward" protocols for individual prostate cancer patients.